archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL Limited and their involvement in clinical trials.
    the laboratory and in animals Clinical trials are carefully supervised monitored and documented The applicable regulatory authority must grant approval to conduct testing in humans and clinical trials are overseen by an independent review body How are clinical trials conducted CSL conducts clinical trials in accordance with the current Guideline for Good Clinical Practice GCP of the International Conference on Harmonisation ICH GCP is an international ethical and scientific quality standard for designing conducting and reporting studies that involve the participation of human subjects Compliance with this standard provides public assurance that the rights safety and well being of study subjects are protected and that the clinical trial data are credible Compliance with this standard also ensures that CSL conducts clinical trials consistent with the principles that have originated in the Declaration of Helsinki Current Studies All Bleeding Disorders Critical Care Immunoglobulins Pulmonary Therapeutic Proteins Vaccines Wound Healing Condition Additional Trial Information Congenital Fibrinogen Deficiency Fibrinogen Concentrate Human Efficacy and Safety Study Learn More Leukemia Myeloid Acute A Study of CSL362 in Patients With CD123 Acute Myeloid Leukemia Currently in Remission Learn More Emphysema Caused by API Deficiency Study of Zemaira i v Administration in Subjects Who Completed a 2 Year Controlled Study With This Treatment and Have Emphysema Due to alpha1 Proteinase Inhibitor Deficiency Learn More Hemophilia A An Open label Safety Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A Learn More Hemophilia A Study of a Plasma Derived von Willebrand Factor Factor VIII Concentrate vWF FVIII Biostate in Subjects with Hemophilia A Learn More Page 1 of 3 Next Last Trial Phases Following a positive outcome in preclinical testing the sponsoring organisation usually a drug manufacturer will seek approval to conduct clinical trials Once approval has

    Original URL path: http://www.csl.com.au/research-development/clinical-trials.htm (2014-01-05)
    Open archived version from archive


  • CSL Limited - Contact Information
    Responsibility Careers Newsroom Contact CSL Home Contact CSL Business in Australia For more information about CSL within this region please contact appropriate section CSL Limited Registered Head Office 45 Poplar Rd Parkville Victoria 3052 Australia Phone 61 3 9389 1911 Fax 61 3 9389 1434 Submit General Enquiries CSL Limited Research and Development 45 Poplar Road Parkville Victoria 3052 Australia Phone 61 3 9389 1911 Fax 61 3 9389 1434 Email cslrd csl com au CSL Behring 189 209 Camp Road Broadmeadows Victoria 3047 Australia Phone 61 3 9246 5200 Fax 61 3 9246 5299 bioCSL 63 Poplar Road Parkville Victoria 3052 Australia Phone 61 3 9389 2000 Fax 61 3 9389 1874 Please contact our medical department for product enquiries or to report an adverse event related to plasma derived therapies pharmaceuticals vaccines or antivenom products Australia 1800 642 865 International 61 3 9389 1932 Customer Service Enquiries for CSL Behring plasma derived therapies Australia 1800 063 892 International 61 3 9246 5231 Email your enquiry Customer Service Enquiries for bioCSL pharmaceutical vaccine and antivenom products Australia 1800 008 275 bioCSL Immunohaematology 63 Poplar Rd Parkville Victoria 3052 Australia Phone 61 3 9389 1919 Fax 61 3 9389 1646

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562651488/content/1196562656332/content.htm (2014-01-05)
    Open archived version from archive

  • CSL - Financial Reports
    our global organisation At the same time looking to future market growth CSL has remained focussed on expanding manufacturing capacity developing new medicines and enhancing financial management 2012 13 Annual Report 4Mb 2012 13 Shareholder Review 1Mb 2012 2013 Financial Report 1Mb Visit the 2012 13 Annual Report Website Half Year Report 2012 2013 Half Year Report 2012 2013 0 3Mb Past Annual and Half Year Reports 2011 2012 2011

    Original URL path: http://www.csl.com.au/investors/financial-reports.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited - Results Briefings
    to the Market and Half year report CSL Half Year Results Announcement for 2012 13 0 03Mb Full Year Results for 2011 12 22 August 2012 Analyst Presentation 0 52Mb ASX Full Year Information 0 15Mb including Results for Announcement to the Market Additional Information Annual Financial Report including Directors Report CSL Full Year results announcement for 20011 12 0 92Mb Half Year Results for 2011 12 22 February 2012 Analyst Presentation 0 55Mb ASX Half Year Information 0 16Mb including Results for Announcement to the Market and Half year report CSL Half Year Results Announcement for 2011 12 0 09Mb Full Year Results for 2010 11 17 August 2011 Full Year Results Webcast Analyst Presentation 0 3Mb ASX Full Year Information 0 6Mb including Results for Announcement to the Market Additional Information Annual Financial Report including Directors Report CSL Full Year results announcement for 20010 11 0 1Mb CSL Announces Changes to the Board Half Year Results for 2010 11 16 February 2011 Analyst Presentation 0 5Mb ASX Half Year Information 0 5Mb including Results for Announcement to the Market and Half year report CSL Half Year Results Announcement for 2010 11 0 1Mb CSL Appoints New Director Full Year Results for 2009 10 18 August 2010 Analyst Presentation 0 43Mb ASX Full Year Information 2Mb including Results for Announcement to the Market Additional Information Annual Financial Report including Directors Report CSL Full Year results announcement for 2009 10 0 25Mb Half Year Results for 2009 10 17 February 2010 Analyst Presentation 0 12Mb ASX Half Year Information 0 35Mb including Results for Announcement to the Market and Half year report CSL Half Year Results Announcement for 2009 10 0 08Mb Full Year Results for 2008 09 19 August 2009 Analyst Presentation 0 10Mb ASX Full Year Information 0

    Original URL path: http://www.csl.com.au/investors/briefings-presentations/results-briefing.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited - Performance Summary
    4 058 3 724 Sales Revenue 5 056 4 950 4 616 4 097 3 909 3 412 R D Investment 434 427 370 323 278 226 Profit before Income Tax Expense 1 492 1 467 1 270 1 167 1 207 1 010 Net Profit 1 234 1 216 1 024 918 921 845 Capital Investment 450 309 197 215 195 Total Assets at 30 June 5 976 5 901 5 447 4 865 5 977 Total Equity at 30 June 3 007 3 477 3 917 3 591 4 432 Net Tangible Assets per share at 30 June 4 41 5 15 5 68 5 10 6 08 Weighted Average Number of Shares million 499 519 541 567 595 Basic Earnings per Share cents 2 439 1 972 1 698 1 625 1 420 Dividend per Share cents 1 020 0 865 0 781 0 700 0 516 Financial Performance in US 3 1 The Group s Reported results are reported in accordance with the Australian Equivalents to International Financial Reporting Standards A IFRS 2 Constant currency removes the impact of exchange rate movements to facilitate comparability by restating the current year s rates For further details please

    Original URL path: http://www.csl.com.au/investors/five-year-summary.htm (2014-01-05)
    Open archived version from archive

  • CSL - Limited R&D and Operational Briefings
    Event Calendar Shareholder Information Corporate Responsibility Careers Newsroom Contact CSL Home Investors R D and Operational Briefings R D and Operational Briefings Current Presentations 05 December 2013 R D Briefing December 2013 7Mb Previous Presentations 17 June 2013 Chief Financial Officer presentation to investors at UBS Healthcare Conference in Sydney 0 2Mb 06 December 2012 R D Briefing December 2012 4Mb 08 December 2011 R D Briefing December 2011 4

    Original URL path: http://www.csl.com.au/investors/briefings-presentations/operational-briefing.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited - Corporate Profile
    creation of state of the art plasma collection and manufacturing facilities our investment in improving current therapies finding new indications for existing therapies and innovating new therapeutic products for unmet needs The CSL Board Executive Management Our Businesses CSL Limited has over 10 000 staff in more than 20 countries Our headquarters is in Australia and we have substantial manufacturing operations in the US Germany and Switzerland The CSL Group includes bioCSL incorporating Immunohaematology and CSL Behring incorporating CSL Plasma We support patient biomedical and local communities by improving access to therapies enhancing patients quality of life advancing scientific knowledge supporting future medical researchers and engaging our staff in the support of local communities We also contribute to humanitarian programs and relief efforts around the world CSL Behring website bioCSL website Research Development CSL are committed to significantly investing in its future R D portfolio and capabilities in the areas of immunoglobulins specialty products haemophilia products and breakthrough medicines This commitment to funding research and development of protein based medicines for unmet medical needs underpins its continued growth Product Pipeline Recent Highlights Our Products CSL is a leading manufacturer in a US 7 5 billion plasma industry CSL is also

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378980806/content/1255929310417/content.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited - Dividends
    Interim 13 Sep 12 Mar 4 Oct 5 Apr 56 98 48 66 0 0 30 30 N A N A 2012 Final Interim 21 Sep 20 Mar 12 Oct 13 Apr 47 36 0 0 30 30 N A N A 2011 Final Interim 23 Sep 15 Mar 14 Oct 8 Apr 45 35 4 4 0 30 30 N A N A 2010 Final Interim 17 Sep 15 Mar 8 Oct 9 Apr 45 35 11 0 30 30 N A N A 2009 Final Interim 18 Sep 16 Mar 9 Oct 9 Apr 40 30 0 0 30 30 N A N A 2008 Final Interim 22 Sep 20 Mar 10 Oct 14 Apr 23 23 100 0 30 30 N A N A 2007 Final Interim 21 Sep 20 Mar 12 Oct 13 Apr 55 49 50 0 30 30 N A N A 2006 Final Interim 22 Sep 20 Mar 13 Oct 13 Apr 40 28 0 0 30 30 N A N A 2005 Final Special Interim 5 Sep 5 Sep 15 Mar 10 Oct 10 Oct 15 Apr 30 10 17 100 17 8 100 30 30 30 N A N A N A 2004 Final Interim 24 Sep 2 Apr 8 Oct 13 Apr 26 12 100 100 30 30 AUD 27 83 AUD 22 30 2003 Final Interim 26 Sep 4 Apr 10 Oct 15 Apr 22 12 100 100 30 30 AUD 16 65 N A 2002 Final Interim 26 Sep 11 Apr 10 Oct 23 Apr 22 12 100 100 30 30 N A N A 2001 Final Interim 27 Sep 11 Apr 11 Oct 24 Apr 17 9 100 100 30 34 N A N A 2000 Final Interim 28 Sep 12 Apr 12 Oct 26 Apr 15

    Original URL path: http://www.csl.com.au/investors/dividends.htm (2014-01-05)
    Open archived version from archive